NOW ENROLLING IN PLAQUE PSORIASIS

For adults with moderate to severe plaque psoriasis

PF-06826647 is an investigational TYK2 inhibitor. The kinase activity of TYK2 may play a role in the pathophysiology of several autoimmune diseases. This is a phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of PF-06826647 in subjects with moderate to severe plaque psoriasis.

Planned country for recruitment: United States.

STUDY DESIGN

CLINICAL ENDPOINTS

ELIGIBILITY CRITERIA

TYK2: tyrosine kinase.

REQUEST INFORMATION

REFERENCES

Pfizer CT.gov
Call Center: 1-800-718-1621
ClinicalTrials.gov_inquiries@pfizer.com

Efficacy and safety of these compounds, for the uses identified within, have not been established and are currently under investigation. Regulatory approval of any of these compounds or uses is dependent on the completion of the study programs and review and approval by regulatory authorities. This is not a complete representation of all Pfizer pipeline compounds. This information is current as of July 2019. The clinical trial information is available at www.clinicaltrials.gov.
NOW ENROLLING IN PLAQUE PSORIASIS

For adults with moderate to severe plaque psoriasis

PF-06826647 is an investigational TYK2 inhibitor. The kinase activity of TYK2 may play a role in the pathophysiology of several autoimmune diseases. This is a phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of PF-06826647 in subjects with moderate to severe plaque psoriasis. Planned country for recruitment: United States.

STUDY DESIGN

Primary endpoints:
- Change from baseline of subjects with a Psoriasis Area and Severity Index (PASI) response at week 16
- Number of subjects with adverse events at week 16 through follow-up at week 44
- Number of subjects with a clinically significant change in vital signs through week 40
- Number of subjects with a clinically significant treatment-emergent electrocardiogram finding through week 40
- Number of subjects with a change in laboratory test results through week 40

Key selected secondary endpoints:
- Percentage of subjects with a PASI 50, PASI 75, and PASI 100 response at week 16
- Percentage of subjects with Physician’s Global Assessment (PGA) of psoriasis score of “clear” or “almost clear” at week 16
- Percent change and absolute score of Peak Pruritus Numerical Rating Scale (NRS) score at week 16

TYK = tyrosine kinase.

*Clinically significant electrocardiogram findings include corrected QT (QTc) >450 milliseconds, QTc >500 milliseconds, change in QTc between 30 and 60 milliseconds, and change in QTc greater than or equal to 60 milliseconds.

Efficacy and safety of these compounds, for the uses identified within, have not been established and are currently under investigation. Regulatory approval of any of these compounds or uses is dependent on the completion of the study programs and review and approval by regulatory authorities.

This is not a complete representation of all Pfizer pipeline compounds. This information is current as of July 2019. The clinical trial information is available at www.clinicaltrials.gov.
**NOW ENROLLING IN PLAQUE PSORIASIS**

For adults with moderate to severe plaque psoriasis\(^{12}\)

PF-06826647 is an investigational TYK2 inhibitor.\(^{15}\)

The kinase activity of TYK2 may play a role in the pathophysiology of several autoimmune diseases.\(^{23-26}\)

This is a phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of PF-06826647 in subjects with moderate to severe plaque psoriasis.\(^{21}\)

Planned country for recruitment: United States.\(^{12}\)

---

### STUDY DESIGN

#### Key selected inclusion criteria\(^ {12}\)

- 18 to 75 years of age with a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months
- PASI score of 12 or greater AND PGA score of 3 (moderate) or 4 (severe)
- Plaque-type psoriasis covering at least 10% of total BSA

### CLINICAL ENDPOINTS

#### Key selected exclusion criteria\(^ {12}\)

- Non-plaque forms of psoriasis
- Drug-induced psoriasis
- Current active infection, including Mycobacterium tuberculosis (TB)
- Any history of malignancies
- Require treatment with prohibited concomitant medication(s)
- Positive for hepatitis B or C viruses, or HIV

---

BSA=body surface area; PASI=Psoriasis Area and Severity Index; PGA=Physician's Global Assessment; TYK=tyrosine kinase.